Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer (ARRY)

Jun 17 2019 by Business Insider

 

Pfizer agreed to purchase Array BioPharma for $11 billion.  Array Biopharma specializes in the development and commercialization of drugs to treat cancer and other high burden diseases.  There have been several large healthcare acquisitions in 2019 focused on drugs to treat cancer. 

Array BioPharma rose more than 50% before the opening bell on Monday after Pfizer offered $11 billion to buy the biotechnology company.

Pfizer is offering $48 a share for Array, which represents around a 62%...

Continue Reading Array BioPharma spikes more than 50% after Pfizer shells out $11 billion for the cancer-drug developer (ARRY)